Gamma-delta T-cell lymphoma of the central nervous system: A case report and review of the literature
We describe a case of TCL presenting in the basal ganglia with γδ receptor expression and a remarkably aggressive clinical course. To the best of our knowledge, this is the fifth reported case of γδ TCL presenting in the CNS. We review existing literature, including the previously reported cases of γδ TCL of the CNS. In our case, a 69-year-old male presented with acute onset dysarthria and right-sided weakness, with initial imaging concerning for stroke. Repeat imaging demonstrated a 2.6-cm mass in the left basal ganglia-corona radiata. Pathologic examination of a stereotactic biopsy revealed TCL with γδ receptor p...
Source: Clinical Neuropathology - March 22, 2024 Category: Pathology Authors: Alexa T Andre Meagan Chambers Daniel E Sabath Source Type: research
How does deep learning/ machine learning perform in comparison to radiologists in distinguishing Glioblastomas (or grade IV Astrocytomas) from Primary CNS Lymphomas?: A meta-analysis and systematic review
Several studies have been published comparing deep learning (DL)/machine learning (ML) to radiologists in differentiating PCNSLs from GBMs with equivocal results. We aimed to perform this meta-analysis to evaluate the diagnostic accuracy of ML/DL versus radiologists in classifying PCNSL versus GBM using MRI. (Source: Clinical Radiology)
Source: Clinical Radiology - March 19, 2024 Category: Radiology Authors: Amrita Guha, Soutik Halder, Shubham H. Shinde, Jitendra Gawde, Satish Munnolli, Sanjay Talole, Jayant S. Goda Source Type: research
How does deep learning/machine learning perform in comparison to radiologists in distinguishing glioblastomas (or grade IV astrocytomas) from primary CNS lymphomas?: a meta-analysis and systematic review
Several studies have been published comparing deep learning (DL)/machine learning (ML) to radiologists in differentiating PCNSLs from GBMs with equivocal results. We aimed to perform this meta-analysis to evaluate the diagnostic accuracy of ML/DL versus radiologists in classifying PCNSL versus GBM using MRI. (Source: Clinical Radiology)
Source: Clinical Radiology - March 19, 2024 Category: Radiology Authors: A. Guha, S. Halder, S.H. Shinde, J. Gawde, S. Munnolli, S. Talole, J.S. Goda Source Type: research
Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders
Handb Clin Neurol. 2024;200:239-273. doi: 10.1016/B978-0-12-823912-4.00020-7.ABSTRACTPeripheral neuropathy is a common referral for patients to the neurologic clinics. Paraneoplastic neuropathies account for a small but high morbidity and mortality subgroup. Symptoms include weakness, sensory loss, sweating irregularity, blood pressure instability, severe constipation, and neuropathic pain. Neuropathy is the first presenting symptom of malignancy among many patients. The molecular and cellular oncogenic immune targets reside within cell bodies, axons, cytoplasms, or surface membranes of neural tissues. A more favorable imm...
Source: Clinical Lymphoma and Myeloma - March 17, 2024 Category: Cancer & Oncology Authors: Shahar Shelly Divyanshu Dubey John R Mills Christopher J Klein Source Type: research
Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders
Handb Clin Neurol. 2024;200:239-273. doi: 10.1016/B978-0-12-823912-4.00020-7.ABSTRACTPeripheral neuropathy is a common referral for patients to the neurologic clinics. Paraneoplastic neuropathies account for a small but high morbidity and mortality subgroup. Symptoms include weakness, sensory loss, sweating irregularity, blood pressure instability, severe constipation, and neuropathic pain. Neuropathy is the first presenting symptom of malignancy among many patients. The molecular and cellular oncogenic immune targets reside within cell bodies, axons, cytoplasms, or surface membranes of neural tissues. A more favorable imm...
Source: Clinical Lymphoma and Myeloma - March 17, 2024 Category: Cancer & Oncology Authors: Shahar Shelly Divyanshu Dubey John R Mills Christopher J Klein Source Type: research
Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5(+) diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report
CONCLUSIONS: These findings suggest that toripalimab may be a new therapeutic option for central nervous system recurrence in refractory CD5+ DLBCL with MYD88 and CD79B comutation. Further clinical trials are warranted to confirm these results.PMID:38482415 | PMC:PMC10928622 | DOI:10.21037/tcr-23-1638 (Source: Cell Research)
Source: Cell Research - March 14, 2024 Category: Cytology Authors: Xi Chen Zhihan Zhang Junbao Zhang Qiuxiao Yu Junjing Qiu Yajie Xiao Binbin Chen Ping Xu Source Type: research
Cancers, Vol. 16, Pages 1157: Histopathological Diagnosis of Primary Central Nervous System Lymphoma after Therapy with Corticosteroids or Anticoagulants
In conclusion, preoperative CS therapy can challenge the histological diagnosis of PCNSL. At the same time, our data suggest that preoperative CS treatment only presents a relative contraindication for early surgical intervention. If a definitive diagnosis cannot be made after the first surgical intervention, the timing of a repeat biopsy after the discontinuation of CS remains a case-by-case decision. The effect of anticoagulation and dual antiplatelet therapy on diagnostic accuracy might have been underestimated and should be examined closely in future investigations. (Source: Cancers)
Source: Cancers - March 14, 2024 Category: Cancer & Oncology Authors: Julia Feldheim Marvin Darkwah Oppong Jonas Alexander Feldheim Ramazan Jabbarli Philipp Dammann Anne-Kathrin Uerschels Oliver Gembruch Yahya Ahmadipour Cornelius Deuschl Andreas Junker Ulrich Sure Karsten Henning Wrede Tags: Article Source Type: research
Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma
ConclusionOn the basis of this study, we propose that PCNSL patients should receive early induction therapy with sufficient cycles. Subsequent consolidation therapy can prevent relapses and improve survival. In patients with PCNSL, the independent prognostic factors for OS and PFS were CSF LDH level, NLR, and full cycles of induction therapy. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - March 11, 2024 Category: Cancer & Oncology Source Type: research
Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma
ConclusionsIn this study, the IELSG score was improved and a new prognostic indicator POD18 was incorporated to construct a nomogram prognostic model, thereby further improving the predictive ability of the model. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 1, 2024 Category: Cancer & Oncology Source Type: research
Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan
We report a case of isolated CNS recurrence of bilateral PTL. Our patient achieved complete response (CR) after rituximab-combination chemotherapy for PTL. Approximately five years later, isolated CNS recurrence of PTL occurred. Our patient achieved CR again after high-dose methotrexate therapy and autologous stem cell transplantation (ASCT) with a conditioning regimen of thiotepa and busulfan as a consolidation therapy. The secondary failure of platelet recovery, probably caused by busulfan, occurred after the platelet engraftment. Our patient has remained in CR for over three years. The treatment strategy for CNS recurre...
Source: Journal of Clinical and Experimental Hematopathology : JCEH - February 28, 2024 Category: Hematology Authors: Yasuhiro Tanaka Tomomi Sakai Hiroko Tsunemine Tomoo Ito Nobuyoshi Arima Source Type: research
